Dr J J Misiewicz (MRC Gastroenterology Unit, Central Middlesex Hospital, London NWJ0) Some Effects of Prostaglandins in Man Rapid advance in the prostaglandin (PG) field which began with elucidation of their chemical structure (Bergstrom et al. 1963 ) is reflected in the escalating number of publications dealing with effects of PGs in various animals; by comparison the knowledge of their actions in man is meagre. This paper briefly reviews some of their effects in the human. The effects of PGs on the reproductive tract, bronchial smooth muscle and gastrointestinal smooth muscle in vitro, are dealt with elsewhere in this symposium, as are the possible diarrhoeal effects of PGs released from certain tumours. With the notable exception of the latter, most reported effects in man have been caused by PG administered by various routes rather than by PGs released spontaneously in the body, making the assessment of the biological role of these compounds difficult; moreover the majority of better documented phenomena are due to the excitatory or inhibitory actions of PG on smooth muscle cells.
Intravenous infusion of PGE1 is accompanied by flushing of the face (and in some cases, of the upper limbs), headache, palpitations, a feeling of constriction of the chest and abdominal cramps or pain. These symptoms do not appear at 2-8 ,ug/min (Embrey 1970) and are relatively minor at lower infusion rates (0 058-01 ,ug/kg/min), but become more marked with increasing doses, the tolerable limit for PGE1, varying from 0 032 to 0 58 ,ug/kg/min (Bergstrom et al. 1959 ). Other PGs may be better tolerated and infusions of 50 ,ug/min of PGF2a produced only mild diarrhoea or vomiting in 10 of 15 women, whilst 5 males suffered no side-effects with PGF2a in doses up to 150 ,ug/min; none of these subjects exhibited cardiovascular or respiratory changes (Karim & Filshie 1970) .
The circulatory responses accompanying infusions of PGE1 have been studied in detail by Carlson et al. (1969) ; they consist of a hyperkinetic circulation, characterized by increased heart rate and stroke volume, decreased peripheral resistance and A/V 02 differencechanges consistent with peripheral arteriolar dilatation. The vasodepressor properties of PGs in relation to hypertension have been explored in a preliminary way by several workers. Lee et al. (1969) reported that intravenous PGA1 at 0-1-0 3 ,ug/kg/min left the blood pressure of patients suffering from essential hypertension unaffected, whilst some lowering of blood pressure was noted in a patient given 2-3 pg/kg/min. Daily infusions of 1-2 mg of PGA1 for up to six consecutive days lowered the systolic and diastolic pressure in five of six hypertensive patients, but the blood pressure rebounded on stopping the treatment (Christlieb et al. 1969) . Edwards et al. (1969) reported the interesting observation that a vasodepressor lipid resembling PGE2 was found in renal venous blood of hypertensives, higher concentrations of the vasoactive material appearing in the blood from the more severely affected kidney; whilst in two other patients who had had a succes5ful repair of renal artery stenosis, the vasodepressor lipid was undetectable. Natriuretic effects of PGA1 in man have been reported by Fichman (1969) . All these observations emphasize the interest in the role of PG in the regulation of renal blood flow and the handling of sodium and water by the renal tubule in the normotensive and hypertensive kidney.
Little is known about the metabolism and metabolic effects of PGs in man. Tritiated PG is rapidly removed from the circulation, 40% of radioactivity appearing in the urine and 20% in the frces (Granstrom 1967): the major metabolite of PGE2 has been identified in the urine (Hamberg & Samuelsson 1969) . PGE1 is one of the most powerful inhibitors of lipolysis known.
At a concentration of 10 ng/ml PGE, reduces the basal release of glycerol from human subcutaneous tissue in vitro, but omental fat tissue is less responsive. Concentrations of 1 pg/ml of PGE1 were required to inhibit noradrenaline-stimulated glycerol release from either tissue (Carlson 1965 , Carlson & Hallberg 1968 . The predominant effect in vivo of intravenous PGE1 is to raise the concentration of free fatty acids and glycerol, but only a slight inhibition of similar changes due to noradrenaline has been recorded (Bergstrom et al. 1965 ), so that the importance of PG as a local regulator of lipolysis in man remains to be defined.
Effects of PG on the gastrointestinal tract of laboratory animals are of interest in relation to man on several counts. Various investigators have reported the inhibition of gastric acid secretion itt vivo or in vitro (Robert et al. 1967 , Shaw & Ramwell 1968 , Ramwell & Shaw 1968 , Robert 1968 , Lippman 1969 ). These findings are not only of theoretical interest in relation to the role of PGs as local regulators of acid secretion via the adenyl cyclase system (Horton 1969 ), but also may have possible clinical implications in the treatment of peptic ulcer. This suggestion is reinforced by the observation that PGE, prevents the development of ulcers in the rat stomach after ligation of the pylorus or administration of steroids (Robert et al. 1968 ). On the other hand, Horton et al. (1968) could not demonstrate any effect of oral PGE1 on pentagastrin-stimulated acid output in man. The bowel looseness after ingestion of PGE1 noted by those authors is due to accelerated transit through both the small and the large intestine (Misiewicz et al. 1969 ), but the relevance of these findings to the diarrheea occurring with tumours is uncertain. Nor is it known whether PGs participate in the causation of other diarrhceal states, e.g. choleraic diarrhoea, although such a hypothesis has been postulated by Greenough et al. (1969) on the basis of studies in dogs.
The field therefore bristles with exciting possibilities, but because of variability of responses of different tissues to various PGs, and because of species differences and technical pitfalls, conclusions should be drawn with caution (Pickles 1969 Bronchodilator Activity of Aerosols of Prostaglandins E1 and E2 in Asthmatic Subjects Although the prostaglandins have been intensely studied since 1962, when the chemical structure of the first member was determined, the effects on bronchial smooth muscle have until recently received little attention. Main (1964) showed that prostaglandin E1 (PGE1) relaxes isolated tracheal smooth muscle of the guinea-pig and Sweatman & Collier (1968) showed that this prostaglandin relaxes isolated human bronchial muscle.
A recent study has demonstrated that PGE1 and isoprenaline have similar bronchodilator activity in anesthetized guinea-pigs when injected intravenously but, when given by aerosol, PGE1 is 10-100 times more active than isoprenaline. The bronchodilator effect was not antagonized by propranolol, a beta-adrenergic receptor blocker. Studies in the anesthetized monkey, however, failed to reveal any bronchodilator activity by either route (Large et al. 1969 ).
In the present study the forced expiratory volume in one second (FEV1) was measured by a Vitalograph in healthy and asthmatic volunteers and the effect of an inhalation of PGE1 was compared with that of isoprenaline and placebo, using metered aerosols. Blood pressure was measured at frequent intervals using a modified mercury sphygmomanometer and pulse rate was calculated from the electrocardiogram which was displayed continuously. A preliminary report of the results has been published (Cuthbert 1969).
Results
Healthy volunteers: Graded doses of PGE1 (free acid) in the range 0-275 to 27-5 pg were given by aerosol to 6 subjects. There was no alteration in FEV1 following the inhalation, but 3 subjects noticed some irritation of the upper respiratory tract. Doses of 55 pg PGE1 consistently caused coughing and this preparation was therefore unsatisfactory for use in asthmatic subjects.
It was thought that the irritant effect might be due to the presence of PGE1 as the free acid. The aerosol was therefore reformulated as the neutral triethanolamine salt and the study repeated in healthy volunteers. Again there was no alteration in FEV1 following the inhalation and only 2 of the subjects noticed slight irritation of the upper respiratory tract with the 55 pg dose. Asthmatic volunteers: The triethanolamine salt of PGE1 was used in all studies on asthmatic volunteers. Preliminary experiments showed that small doses (2 75-27 5 pg) had a bronchodilator effect in 5 asthmatic subjects with reversible airways obstruction. There was a 20-40 % increase in FEVy and the total duration of the effect was 15 to 35 minutes.
A comparison was made between PGE1 (triethanolamine salt) 55 pg, isoprenaline sulphate 550 pg, and placebo. The treatments were administered blind according to a Latin square design. The block consisted of all possible combinations of three treatments allocated randomly. The results are shown in Table 1 (see also Cuthbert 1969) . In all of the subjects the inhalation of PGE1 caused an increase in FEV1 which was comparable in both degree and duration to that of isoprenaline. There was no change in blood pressure, pulse rate or electrocardiogram in any of the subjects. The effect of PGE1 appeared less rapidly than that of isoprenaline, but there appeared to be little difference in the overall effect of the two preparations.
None of the asthmatic subjects who took part in the study found the preparation of PGE1 (triethanolamine salt) to be irritant to the upper
